title: Information for decision making by post-menopausal women with hormone receptor positive early-stage breast cancer considering adjuvant endocrine therapy.
abstract: OBJECTIVE
  To identify the information that post-menopausal women with hormone-receptor positive, early-stage breast cancer want, to help them decide among six treatment options for adjuvant-endocrine therapy.
  
  
  METHODS
  We surveyed women with early-stage breast cancer who were eligible for adjuvant endocrine-therapy 3-18 months earlier. Participants rated the importance of getting each of 95 questions answered before this decision is made (options: essential/desired/not important/avoid). For questions rated essential or desired, participants identified the purpose(s) for having the question answered: to help them understand, make the decision, plan, or other. Participants indicated the role they played in their actual decision and the role they would prefer if the decision was made today. They also indicated whether they felt they had had a choice of endocrine therapy treatments.
  
  
  RESULTS
  188 of 343 questionnaires were returned (response rate 55%). Mean age was 67 yr (range 38-88 yr); 76% were married, and 39% had secondary school education or less. On average, respondents rated 18 questions (range 0-94) essential for decision making. Each question was rated essential for decision making by ≥ 7% of participants but only 1 question by >50%. Regarding roles, 89% of respondents had participated in their actual decision and would want to again; an additional 9% had not participated in their actual decision but would want to at the time of the survey. The percentage of respondents who felt they had no choice of endocrine therapy treatments varied between centres, 25% vs 41% and 49%.
  
  
  CONCLUSIONS
  Most patients want to participate in the decision but they vary widely in the amount and which specific details they want to help them make the decision.
  
  
  CONCLUSIONS
  The wide variation in questions considered important means the support should be tailored to the needs of the individual patient.
authors.affiliation: Division of Cancer Care and Epidemiology, Cancer Research Institute, Queen's University, Kingston, Canada; Dept of Oncology, Queen's University, Kingston, Canada. Electronic address: deb.feldman-stewart@krcc.on.ca.
authors.forename: Deb
authors.initials: D
authors.lastname: Feldman-Stewart
authors.forename: Yolanda
authors.initials: Y
authors.lastname: Madarnas
authors.forename: Mihaela
authors.initials: M
authors.lastname: Mates
authors.forename: Christine
authors.initials: C
authors.lastname: Tong
authors.forename: Eva
authors.initials: E
authors.lastname: Grunfeld
authors.forename: Shailendra
authors.initials: S
authors.lastname: Verma
authors.forename: Hannah
authors.initials: H
authors.lastname: Carolan
authors.forename: Michael
authors.initials: M
authors.lastname: Brundage
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003657:Decision Making; D005260:Female; D006801:Humans; D008875:Middle Aged; D020380:Needs Assessment; D010353:Patient Education as Topic; D010358:Patient Participation; D017698:Postmenopause; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D011795:Surveys and Questionnaires
chemical_list: D018931:Antineoplastic Agents, Hormonal; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human
keywords: Adjuvant endocrine therapy decision; Breast cancer; Patient decision making